

# Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in *APOE\*3-Leiden* Mice

Marit Westerterp, Caroline C. van der Hoogt, Willeke de Haan, Erik H. Offerman, Geesje M. Dallinga-Thie, J. Wouter Jukema, Louis M. Havekes, Patrick C.N. Rensen

**Objective**—The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is still undergoing debate. Therefore, we evaluated the effect of human CETP expression on atherosclerosis in *APOE\*3-Leiden* (*E3L*) mice with a humanized lipoprotein profile.

**Methods and Results**—*E3L* mice were crossbred with human *CETP* transgenic mice. On a chow diet, CETP expression increased plasma total cholesterol (TC) (+43%;  $P < 0.05$ ). To evaluate the effects of CETP on the development of atherosclerosis, mice were fed a Western-type diet containing 0.25% cholesterol, leading to 4.3-fold elevated TC levels in both *E3L* and *CETP.E3L* mice ( $P < 0.01$ ). On both diets, CETP expression shifted the distribution of cholesterol from high-density lipoprotein (HDL) toward very-low-density lipoprotein (VLDL)/low-density lipoprotein (LDL). Moreover, plasma of *CETP.E3L* mice had reduced capacity (−39%;  $P < 0.05$ ) to induce SR-BI-mediated cholesterol efflux from Fu5AH cells than plasma of *E3L* mice. After 19 weeks on the Western-type diet, *CETP.E3L* mice showed a 7.0-fold increased atherosclerotic lesion area in the aortic root compared with *E3L* mice ( $P < 0.0001$ ).

**Conclusions**—CETP expression in *E3L* mice shifts the distribution of cholesterol from HDL to VLDL/LDL, reduces plasma-mediated SR-BI-dependent cholesterol efflux, and represents a clear pro-atherogenic factor in *E3L* mice. We anticipate that the *CETP.E3L* mouse will be a valuable model for the preclinical evaluation of HDL-raising interventions on atherosclerosis development. (*Arterioscler Thromb Vasc Biol.* 2006;26:2552-2559.)

**Key Words:** CETP ■ cholesterol efflux ■ hyperlipidemia ■ reverse cholesterol transport ■ transgenic mice

Cardiovascular disease (CVD) is the leading cause of death in the Western world and its prevalence is increasing in Eastern Europe and developing countries.<sup>1</sup> The main cause of CVD is atherosclerosis, characterized by the combination of chronic inflammation and/or hyperlipidemia.<sup>1</sup> Both low high-density lipoprotein (HDL) cholesterol plasma levels and high very-low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) cholesterol levels are independent risk factors for atherosclerosis development.<sup>2</sup> The ratio of VLDL/LDL to HDL is to a great extent affected by the cholesteryl ester transfer protein (CETP).<sup>3</sup>

CETP is a transfer factor that mediates the exchange of cholesteryl esters (CE) and triglycerides (TG) between the apoB-containing lipoproteins (ie, chylomicrons, VLDL, and LDL) and HDL in plasma.<sup>3</sup> As such, CETP may be anti-atherogenic by facilitating reverse cholesterol transport (RCT) from peripheral tissues to the liver via the VLDL/LDL pathway. Another potential role of CETP in RCT has recently

been supported by the observation that CETP mediates HDL-CE uptake by hepatocytes independently of SR-BI and the LDL receptor (LDLr) in vitro.<sup>4</sup> However, CETP may be pro-atherogenic by enhancing the levels of VLDL/LDL with concomitant reduction of anti-atherogenic HDL levels.

Many studies in humans have been performed regarding the association between CETP and lipoprotein levels and the subsequent development of CVD.<sup>5-9</sup> For example, CETP deficiency that was observed in a Japanese population increased CVD despite increased HDL levels.<sup>8,9</sup> In contrast, high CETP concentrations are associated with a faster atherosclerosis progression in men with proven CVD.<sup>6</sup> This finding is corroborated by a correlation study in humans, which showed that the Taq1B polymorphism in CETP is associated with increased plasma CETP, decreased plasma HDL, and an increased progression of CVD.<sup>7</sup> However, this might be confined to hypertriglyceridemic subjects as it has been shown in the prospective EPIC-Norfolk study that

Original received June 1, 2006; final version accepted August 16, 2006.

From The Netherlands Organization for Applied Scientific Research-Quality of Life (M.W., C.C.v.d.H., W.d.H., J.W.J., L.M.H., P.C.N.R.), Department of Biomedical Research, Gaubius Laboratory, CE Leiden, The Netherlands; Departments of General Internal Medicine, Endocrinology, and Metabolic Diseases (M.W., C.C.v.d.H., W.d.H., E.H.O., L.M.H., P.C.N.R.), and Cardiology (J.W.J.), Leiden University Medical Center, RC Leiden, The Netherlands; Laboratory of Vascular Medicine (G.M.D.-T.), Erasmus Medical Center, DR Rotterdam, The Netherlands.

Correspondence to Marit Westerterp, Leiden University Medical Center, Department Endocrinology and Metabolism, C4-R, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail M.Westerterp@lumc.nl

M.W. and C.C.v.d.H. contributed equally to this work.

© 2006 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol.* is available at <http://www.atvbaha.org>

DOI: 10.1161/01.ATV.0000243925.65265.3c

CETP correlated positively with future CVD risk only in humans with high TG levels ( $>1.7$  mmol/L).<sup>5</sup>

Because the studies in humans have been associative and the effects of CETP expression on lipid metabolism and atherosclerosis gave conflicting results, the role of CETP has been addressed in mice that are naturally deficient for CETP.<sup>10</sup> To evaluate the direct effect of CETP on atherosclerosis development, CETP transgenic mouse models have been generated<sup>11</sup> and crossbred on different genetic backgrounds. CETP expression was found to be anti-atherogenic in *APOC3* and lecithin:cholesterol acyltransferase (*LCAT*) transgenic mice.<sup>12,13</sup> However, these mouse models may not be the preferred models for atherosclerosis studies because *APOC3* and *LCAT* mice develop only very small atherosclerotic lesions.<sup>12,13</sup>

In contrast to *APOC3* and *LCAT* mice, CETP was shown to be pro-atherogenic in *apoe*<sup>-/-</sup> and *ldlr*<sup>-/-</sup> mice.<sup>14</sup> Because those mice exhibit both nearly complete blockage of the clearance of VLDL/LDL particles by the liver, it has been hypothesized that the cholesterol-rich particles that are formed as a result of CETP expression accumulate in the vessel wall of these mice.<sup>14</sup> However, the suitability of these particular mouse models for evaluating the effect of CETP on atherosclerosis development may be limited as the potential effect of CETP in the facilitation of reverse cholesterol transport (RCT) from peripheral tissues to the liver via the VLDL/LDL pathway is expected to be largely reduced by apoE or LDLr deficiency. Furthermore, expression of CETP in *apoe*<sup>-/-</sup> mice resulted in unnaturally elevated TG levels.<sup>14</sup> Finally, the *CETP.APOB* mouse has lipoprotein profiles on a chow diet comparable to normolipidemic humans,<sup>15</sup> but does not develop atherosclerosis unless treated with a cholesterol-rich diet containing cholate,<sup>16</sup> that, next to facilitating cholesterol absorption, induces chronic inflammation.<sup>17</sup>

In the present study, we crossbred the human *CETP* transgenic mouse<sup>11</sup> with the *APOE\*3-Leiden* (*E3L*) mouse.<sup>18</sup> The *E3L* mouse expresses a mutation of the human *APOE3* gene resulting in a slightly attenuated clearance of apoB-containing particles via the LDLr pathway.<sup>19</sup> As a result, cholesterol and TG levels are only moderately increased on a chow diet.<sup>19</sup> On a Western-type diet containing 0.25% cholesterol, these mice exhibit a more humanized lipoprotein cholesterol distribution.<sup>20</sup> Its VLDL cholesterol levels are highly susceptible to cholesterol levels in the diet, whereas VLDL-TG levels decline to a normotriglyceridemic human level.<sup>20</sup> In the present study, we thus aimed to investigate the effect of CETP on atherosclerosis development in this humanized mouse model.

## Methods

### Animals and Diet

Human *CETP* transgenic mice expressing the human *CETP* gene under control of its natural flanking regions (strain 5203, heterozygous expression of *CETP*),<sup>11</sup> were obtained from Jackson Laboratories (Bar Harbor, Me), and were crossbred with *E3L* mice,<sup>18</sup> of which female mice were used for experiments. *CETP.E3L* and *E3L* mice were housed under standard conditions with a 12-hour light cycle (7:00 AM to 7:00 PM) and were fed ad libitum with regular chow. Blood samples were collected by tail vein bleeding 1 week before feeding the mice a Western-type diet (semi-synthetic cholesterol-rich

diet, containing 15% [w/w] fat and 0.25% [w/w] cholesterol) (Diet W; Hope Farms, Woerden, The Netherlands) and every 4 weeks thereafter. Hereto, mice were fasted for 4 hours with food withdrawal at 9:00 AM as described previously.<sup>21</sup> The experiments were approved by the institutional Ethical Committee on Animal Care and Experimentation.

### Lipid and Lipoprotein Analysis

Plasma TC and TG levels were determined using enzymatic kits 236691 and 11488872 (Roche Molecular Biochemicals, Indianapolis, Ind), respectively. For determination of the lipid distribution over plasma lipoproteins by fast performance liquid chromatography, 50  $\mu$ L of pooled plasma from 11 mice per group was injected onto a Superose 6 HR 10/30 column (Åkta System; Amersham Pharmacia Biotech, Piscataway, NJ) and eluted at a constant flow rate of 50  $\mu$ L/min phosphate-buffered saline (PBS), 1 mmol/L EDTA (Sigma), pH 7.4. Fractions of 50  $\mu$ L were collected and assayed for TC and TG using enzymatic assays (Roche Molecular Biochemicals). For the analysis of the apolipoprotein distribution, fractions of 50  $\mu$ L were diluted 1:1 (v/v) in sample buffer (0.125 mol/L Tris, pH 6.8; 4% [wt/vol] SDS, 20% [wt/vol] glycerol; 10% [v/v]  $\beta$ -mercaptoethanol; 0.01% [wt/vol] bromophenol blue). Samples were then applied onto a 4% to 20% Tris Glycine precast polyacrylamide minigel (Gradipore Ltd, French Forest, Australia). Electrophoresis was performed according to manufacturer's instructions. Protein bands were stained with Coomassie Brilliant Blue R250 (Sigma), and apparent molecular masses were identified.

### CETP Activity and Protein Levels

CETP activity in plasma was measured as the transfer of [<sup>3</sup>H]cholesteryl oleate ([<sup>3</sup>H]CO) from exogenous LDL to HDL as described elsewhere.<sup>22</sup> Hereto, 2.5  $\mu$ L of plasma of animals on chow and 0.5  $\mu$ L of plasma of animals on the Western-type diet was added as a CETP source, with and without a preceding precipitation of apoB-containing particles using sodium phosphotungstate in the presence of magnesium chloride.<sup>23</sup> CETP activity was calculated as  $\mu$ mol CE transfer per mL plasma per hour. Plasma CETP mass was analyzed as described previously.<sup>24</sup> In short, a 2-antibody sandwich immunoassay with a combination of the monoclonal antibodies TP1 and TP2 as coating was used. TP20 labeled with digoxigenin was used as secondary antibody.

### Murine apoAI Enzyme-Linked Immunosorbent Assay

Plasma apoAI concentrations were determined using a sandwich enzyme-linked immunosorbent assay (ELISA). Hereto, goat-anti-mouse apoAI polyclonal antibody (ab7614; Abcam plc, Cambridge, UK; dilution 1:1000) was coated overnight onto Costar strips (Costar, Inc, New York, NY) (1  $\mu$ g/mL) at 4°C and incubated with diluted mouse plasma (dilution 1:40400) for 2 hours at room temperature. Subsequently, rabbit-anti-mouse apoAI antibody (ab20453; Abcam; dilution 1:2000) was added and incubated for 1 hour at RT. Finally, horseradish peroxidase (HRP)-conjugated swine-anti-rabbit IgG antibody (SWARPO; dilution 1:2000) was added and incubated for 1 hour at RT. HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, Boxtel, The Netherlands) for 15 minutes at room temperature. Purified mouse apoAI (A23100m; Biodesign International, Saco, Me) was used as a standard.

### Cholesterol Efflux

The effect of macrophage CETP on lipid accumulation and cholesterol efflux was investigated using thioglycollate-elicited peritoneal macrophages from *E3L* and *CETP.E3L* mice. Macrophages were loaded with acetylated LDL (AcLDL) (50  $\mu$ g/mL) and [<sup>3</sup>H]cholesterol (2  $\mu$ Ci/mL) for 48 hours and subsequently half of the cells was lysed to determine the [<sup>3</sup>H]cholesterol association related to cell protein.<sup>25</sup> Cholesterol efflux for a period of 10 hours was assessed in the remainder of those cells, with and without human HDL (50  $\mu$ g/mL) as a cholesterol acceptor.

The capacity of the plasma from mice fed the Western-type diet to induce ABCA1 dependent cholesterol efflux was determined using J774 murine macrophage-like cells. To induce cholesterol loading, J774 cells were incubated with AcLDL (50  $\mu\text{g}/\text{mL}$ ) and [ $^3\text{H}$ ]cholesterol (2  $\mu\text{Ci}/\text{mL}$ ) for 48 hours. Subsequently, cells were incubated without and with 0.3  $\text{mmol}/\text{L}$  8-(4-chlorophenyl thio)adenosine 3':5'-cyclic monophosphate (cAMP analogue; Sigma) for 16 hours to induce ABCA1 expression. Then, J774 macrophages were incubated for 4 hours in the absence or presence of 1% of a plasma pool of 10 mice each. Human apoAI (10  $\mu\text{g}/\text{mL}$ ) and HDL (50  $\mu\text{g}/\text{mL}$ ) served as positive controls. The cAMP-dependent cholesterol efflux from J774 cells was considered the ABCA1-mediated efflux.<sup>26</sup>

The capacity of the plasma from mice fed the Western-type diet to induce SR-BI dependent cholesterol efflux was determined using Fu5AH rat hepatoma cells (generous gift from Dr N. Fournier, Chateau-Malabry, France). First, cells were loaded with cholesterol (30  $\mu\text{g}/\text{mL}$ ) in the presence of [ $^3\text{H}$ ]cholesterol (2  $\mu\text{Ci}/\text{mL}$ ) for 24 hours. Then, cholesterol laden Fu5AH cells were incubated for 4 hours in the absence or presence of 1% of a plasma pool of 10 mice each. Human apoAI (10  $\mu\text{g}/\text{mL}$ ) and HDL (50  $\mu\text{g}/\text{mL}$ ) served as positive controls. Cholesterol efflux was interpreted as the SR-BI-mediated efflux.<sup>27</sup>

### Atherosclerosis Study and Atherosclerotic Lesion Analysis

At 8 weeks of age, *CETP.E3L* and *E3L* littermates were fed the Western-type diet. Mice were euthanized after 19 weeks of diet. Hearts were isolated and fixed in phosphate-buffered 4% formaldehyde, dehydrated and embedded in paraffin, and were cross-sectioned (5  $\mu\text{m}$ ) throughout the entire aortic root area. Per mouse, 4 sections with 40- $\mu\text{m}$  intervals were used for quantification of atherosclerotic lesion area and characterization of lesion severity. Sections were routinely stained with hematoxylin-phloxine-saffron (HPS). Lesion area was determined using Leica Qwin image analysis software (EIS, Asbury, NJ). Atherosclerotic lesions were also categorized for severity, according to the American Heart System for humans,<sup>28</sup> which we have adapted to categorize lesions in mice.<sup>29</sup> Three types of categories were discerned: (1) no lesions (type 0); (2) early lesions were fatty streaks containing only foam cells (type 1 to 3); and (3) advanced lesions showing foam cells in the media and presence of fibrosis, cholesterol clefts, mineralization, and/or necrosis (type 4 to 5). The number observed in each category is expressed as a percentage of the total number of lesions present within one group of mice (*CETP.E3L* or *E3L* control group).

### Statistical Analysis

All data are presented as means  $\pm$  SD. Statistical differences were assessed using the Mann-Whitney *U* test for all experiments, except for the typing of the atherosclerotic lesions, in which statistical differences were determined using the  $\chi^2$  test.  $P < 0.05$  was regarded as statistically significant.

## Results

### Effect of CETP Expression on Lipids and Lipoprotein Profiles on a Chow Diet and a Western-Type Diet

The effect of CETP expression on plasma parameters in *E3L* mice on a chow and a Western type diet are summarized in the Table. On a chow diet, CETP expression resulted in a CETP concentration of  $6.2 \pm 3.3$   $\mu\text{g}/\text{mL}$  and activity of  $0.25 \pm 0.05$   $\mu\text{mol CE}/\text{mL}$  per hour as measured in whole plasma. This CETP concentration is  $\approx 3$ -fold higher than found in normolipidemic humans (ie,  $1.8 \pm 0.6$   $\mu\text{g}/\text{mL}$ ).<sup>30</sup> Precipitation of apoB-containing lipoproteins before determination of CETP concentration and activity did not affect these values (results not shown), indicating that plasma CETP resided specifically on HDL. CETP expression increased

### Plasma Parameters in *E3L* and *CETP.E3L* Mice Fed a Chow Diet and a Western-Type Diet

Genotype	CETP Protein ( $\mu\text{g}/\text{mL}$ )	CETP Activity ( $\mu\text{mol CE}/\text{mL}/\text{h}$ )	TC (mmol/L)	TG (mmol/L)
Chow				
<i>E3L</i>	ND	ND	$3.7 \pm 1.2$	$3.5 \pm 1.1$
<i>CETP.E3L</i>	$6.2 \pm 3.3$	$0.25 \pm 0.05$	$5.3 \pm 2.3^*$	$4.3 \pm 0.6$
Western-type diet				
<i>E3L</i>	ND	ND	$16 \pm 5$	$1.4 \pm 0.5$
<i>CETP.E3L</i>	$72.8 \pm 8.7$	$1.1 \pm 0.5$	$23 \pm 6^\dagger$	$1.9 \pm 1.1$

Plasma was obtained from 7-week-old 4-hour-fasted *E3L* ( $n=10$ ) and *CETP.E3L* ( $n=9$ ) mice on a chow diet, or from 4-hour-fasted *E3L* ( $n=13$ ) and *CETP.E3L* ( $n=15$ ) mice fed a Western-type diet for 19 weeks. Plasma CETP protein, CETP activity, and TC and TG levels were determined and are represented as means  $\pm$  SD.

\* $\dagger$ Significant differences as compared with *E3L* mice. \* $P < 0.05$ ,  $\dagger P < 0.01$ . ND indicates not detectable.


plasma TC levels (+43%;  $P < 0.05$ ), and tended to increase plasma TG levels (+23%).

As compared with the chow diet, the Western-type diet increased TC levels 4.3-fold ( $P < 0.001$ ), whereas TG levels decreased  $\approx 60\%$  ( $P < 0.01$ ), in both mouse groups (Table). Such a decrease in TG has been found consistently on feeding *E3L* mouse a Western-type diet,<sup>20,31,32</sup> although the mechanism has not been elucidated yet. In *CETP.E3L* mice, the Western-type diet increased the plasma CETP concentration 11.7-fold ( $P < 0.001$ ) (Table), with a concomitant increase in plasma CETP activity of 4.4-fold ( $P < 0.05$ ). This led to increased TC levels (+43%;  $P < 0.01$ ) and a tendency to increased TG levels (+26%) in *CETP.E3L* as compared with *E3L* mice (Table).

Lipoprotein fractionation showed that CETP increased cholesterol in VLDL 2-fold and decreased cholesterol in regularly sized HDL (fractions 17 to 22) by  $\approx 25\%$  (Figure 1A). Likewise, the plasma apoAI content was reduced by 25% ( $P < 0.05$ ) (Figure 1D). In addition, the lipoprotein particle eluting in fractions 14 to 16 in *E3L* mice almost disappeared on CETP expression (Figure 1A). This particle was rich in apoE and did not contain apoAI (Figure 1B, 1C), and thus represented large apoE-rich HDL-1, consistent with previous observations.<sup>19</sup> Therefore, CETP expression reduced the cholesterol content in total HDL 2-fold.

### Effect of CETP Expression in *E3L* Macrophages on Cholesterol Uptake and Cholesterol Efflux

To investigate whether macrophage-associated CETP affects the uptake of cholesterol, peritoneal macrophages were isolated from *E3L* and *CETP.E3L* mice and incubated with AcLDL and [ $^3\text{H}$ ]cholesterol. Macrophages from *CETP.E3L* mice showed no different cholesterol uptake as compared with those from *E3L* mice (Figure 2A). Also, CETP expression did not affect cholesterol efflux from macrophages using HDL as a cholesterol acceptor (Figure 2B). Taken together, CETP expression in macrophages did not affect either the uptake or efflux of cholesterol.



**Figure 1.** Effect of CETP on cholesterol distribution among lipoproteins in *E3L* mice fed a Western-type diet containing 0.25% cholesterol. Plasma from 4-hour-fasted *E3L* (white symbols) and *CETP.E3L* mice (black symbols) fed a Western-type diet containing 0.25% cholesterol for 19 weeks was pooled per genotype (n=11 per pool). Lipoproteins were size-fractionated by fast performance liquid chromatography on a Superose 6 column, and the individual fractions were assayed for TC (A). Lipoprotein fractions 14 to 19 were assayed for protein and apparent molecular masses were identified representing apoAI and apoE in female *E3L* (B) and *CETP.E3L* (C) mice. Total apoAI levels were determined using a sandwich ELISA (D).


### Effect of CETP Expression on the Cholesterol-Accepting Capacity of Plasma

We determined the effect of plasma from *E3L* and *CETP.E3L* mice on cellular cholesterol efflux, either from cholesterol-laden cAMP analogue-treated J774 cells (representing ABCA1-mediated efflux)<sup>26</sup> or from Fu5AH cells (representing SR-BI-mediated efflux).<sup>27</sup>

Cholesterol efflux from J774 cells was largely induced in the presence of apoAI, whereas HDL had no effect, which is consistent with ABCA1-mediated efflux (Figure 2C). The ABCA1-dependent cholesterol accepting potencies of plasma of *E3L* and *CETP.E3L* mice were similar (~12%). Cholesterol efflux from Fu5AH cells was hardly induced on incubation with apoAI, yet largely induced on incubation with HDL, consistent with SR-BI-mediated efflux (Figure 2D). Plasma of *CETP.E3L* mice was 39% ( $P < 0.05$ ) less efficient in inducing SR-BI-mediated cholesterol efflux as compared with plasma of *E3L* mice (Figure 3D). Taken together, CETP expression reduced the potency of plasma to mediate SR-BI-dependent cholesterol efflux, without compromising the ABCA1-mediated cholesterol efflux.

### Effect of CETP Expression on Atherosclerosis Development

To investigate the effect of CETP on atherosclerosis development, mice were fed the Western-type diet from 8 weeks of age. In *E3L* mice, plasma cholesterol levels raised up to 16 mmol/L and in *CETP.E3L* mice to 23 mmol/L, which remained stable throughout the whole study (supplemental




**Figure 2.** Effect of CETP expression on cholesterol association and cholesterol efflux. Peritoneal macrophages were isolated from *E3L* (white symbols) and *CETP.E3L* (black symbols). Macrophages were laden with AcLDL (48 hours; 50 μg/mL) in the presence of [<sup>3</sup>H]cholesterol (2 μCi/mL) and the accumulation of label was assessed (A). Subsequently, cholesterol efflux with and without HDL (50 μg/mL) was determined over a period of 10 hours (B). After 4 hours of incubation ABCA1-mediated cholesterol efflux from lipid-laden J774 macrophages (C) and SR-BI-mediated cholesterol efflux from lipid-laden Fu5AH cells (D) was assessed in the absence (control) or presence of apoAI (10 μg/mL) or HDL (50 μg/mL), or a plasma pool from 10 *CETP.E3L* (1%), or *E3L* (1%) mice fed the Western type diet for 19 weeks. \* $P < 0.05$ .

Figure 1, available online at <http://atvb.ahajournals.org>). After 19 weeks of the Western-type diet, the development of atherosclerosis in *E3L* mice was still in the early phase because a lot of segments were either unaffected (type 0) or contained foam cell-rich lesions (type 1 to 3) (Figure 3A, 3B). In contrast, *CETP.E3L* mice developed much more advanced lesions that affected the integrity of the media, contained cholesterol clefts, and showed calcification (type 4 to 5) (Figure 3A, 3B). The much more advanced atherosclerosis in *CETP.E3L* mice was reflected in a 7.0-fold increase in atherosclerotic lesion area (Figure 3C). Collectively, CETP represents a clear pro-atherogenic factor in *E3L* mice.

### Discussion

The role of CETP in atherosclerosis is still undergoing debate.<sup>5-9,12-14</sup> In the present study, the effect of CETP expression on atherosclerosis development was evaluated in *E3L* mice, a mouse model with a more humanized cholesterol distribution over lipoproteins. We found that CETP expres-



**Figure 3.** Effect of CETP on the development of atherosclerotic lesion severity and area in the aortic root. *E3L* (white symbols) ( $n=12$ ) and *CETP.E3L* (black symbols) ( $n=11$ ) mice were euthanized after 19 weeks of Western type diet (containing 0.25% cholesterol) feeding, and hearts were isolated, fixed, dehydrated, and embedded in paraffin. Hearts were cross-sectioned ( $5\ \mu\text{m}$ ) throughout the entire aortic root, and stained with hematoxylin-phloxine-saffron (HPS). Representative pictures are shown (A). Four sections per mouse with  $40\ \mu\text{m}$  intervals were typed and categorized according to lesion severity (B) and the extent of atherosclerosis was quantified (C). Each data point represents the mean lesion area per mouse (C). \*\*\*\* $P<0.0001$ .

sion led to a net shift of cholesterol from HDL toward VLDL, resulting in 2-fold increased VLDL cholesterol plasma levels and 2-fold decreased HDL cholesterol levels. This led to a reduced capacity of the plasma to induce SR-BI-mediated cholesterol efflux, yet did not affect ABCA1-mediated cholesterol efflux. Furthermore, CETP expression resulted in much more advanced atherosclerotic lesions and a 7.0-fold increase in atherosclerotic lesion area in *E3L* mice.

CETP permits bidirectional transfer between apoB-containing lipoproteins and HDL, resulting in net flux of TG from VLDL and LDL to HDL, and net flux of cholesterol from HDL to VLDL and LDL.<sup>33</sup> Because apoE3-Leiden has a reduced affinity for the hepatic LDLr as compared with wild-type apoE, *E3L* mice have increased VLDL cholesterol.<sup>19</sup> CETP expression in *E3L* mice caused an additional increase in VLDL cholesterol, probably by increasing the net cholesterol flux from HDL to VLDL,<sup>33</sup> thereby further impeding VLDL clearance. Furthermore, CETP expression in *E3L* mice reduced HDL levels. Next to a 25% decrease in HDL-2 and HDL-3, as reflected by a decrease in both apoAI and cholesterol in these HDL subpopulations, CETP expression resulted in disappearance of apoAI-deficient and apoE-rich HDL-1, which is present in *E3L* mice.<sup>19</sup> Likewise, CETP expression has been shown to eliminate HDL-1 that accumu-

lates in *LCAT* transgenic mice.<sup>12</sup> Apparently, HDL-1 is a preferential substrate for CETP. This hypothesis is corroborated by the finding that HDL-1 accumulates in CETP-deficient humans.<sup>8,9</sup> The CETP-induced reduction in HDL may be explained by: (1) reduced lipidation of HDL apolipoproteins, resulting in enhanced renal clearance of lipid-poor apoAI; (2) enrichment of HDL in TG, resulting in a more efficient hepatic lipase (HL)-mediated HDL catabolism;<sup>34</sup> and/or (3) direct uptake of HDL-CE by liver-associated CETP, as has recently been proposed by Gauthier et al.<sup>4</sup>

On a chow diet, the CETP concentration in *CETP.E3L* mice was  $\approx 3$ -fold higher than in human plasma.<sup>30</sup> On the Western-type diet, plasma CETP activity and mass were 4-fold and 12-fold increased, respectively, as compared with the chow diet. This indicates that inactive CETP accumulated on HDL on a Western-type via an as yet unidentified mechanism. The observation that a cholesterol-rich diet leads to CETP accumulation in plasma is consistent with previous observations in apoE-deficient and LDLr-deficient mice.<sup>35</sup> Also in humans, a positive correlation between plasma lipid levels and plasma CETP concentration was found.<sup>30</sup> In addition, CETP activity was found to correlate with CETP concentration in both normolipidemic humans and hyperlipidemic humans.<sup>30</sup> In line with hyperlipidemic versus normolipidemic *CETP.E3L* mice, also a higher level of inactive CETP was found in hyperlipidemic versus normolipidemic humans.<sup>30</sup> Regulation of CETP expression involves an liver X receptor-response element<sup>36</sup> that is present in the natural flanking regions of the human CETP transgenic mouse strain that we used for crossbreeding with *E3L* mice.<sup>11</sup> Most likely, the cholesterol diet-induced hypercholesterolemia thus results in increased hepatic cholesterol as well as oxysterols, the natural ligands for the liver X receptor,<sup>37</sup> thereby increasing CETP expression, as reflected by increased plasma CETP levels. A similar mechanism may explain the positive correlation between plasma cholesterol and CETP levels in humans.

In previous studies in *E3L* mice, VLDL cholesterol has been found to correlate well with atherosclerotic lesion area, most probably by initiating atherosclerosis on entry of VLDL into the vascular wall.<sup>19</sup> Specifically, feeding *E3L* mice a high-cholesterol diet as compared with a low-cholesterol diet resulted in 2-fold increased VLDL cholesterol levels and a 2-fold increased atherosclerotic lesion area.<sup>38</sup> We now observed that a similar 2-fold increase in VLDL cholesterol levels as induced by the introduction of CETP in *E3L* mice caused even a 7.0-fold increase in atherosclerotic lesion area. This cannot simply be explained by a CETP-mediated increase in VLDL, and suggests that other mechanisms are involved in this process, which may include a local effect of CETP on lipid accumulation in macrophages and/or the observed reduction in HDL.

We found that the expression of CETP in macrophages did not affect AcLDL-induced foam cell formation or cholesterol efflux to human HDL. This is in contrast with findings in a monkey fibroblast cell line (COS-7), which showed that transfection with a CETP construct induces cholesterol efflux.<sup>39</sup> This seeming discrepancy may be caused by a differ-

ence in CETP expression. However, it is thus unlikely that CETP expression in macrophages contributed to the observed increased atherosclerosis development by affecting the cellular lipid homeostasis.

Alternatively, CETP may affect RCT by reducing plasma levels of HDL, which is crucially involved in RCT. The first step in this process is cholesterol efflux from the macrophage, as mediated by ABCA1 and SR-BI. The shift of plasma cholesterol from HDL to VLDL as induced by CETP expression did not affect ABCA1-mediated cholesterol efflux yet reduced SR-BI-mediated efflux. It has been shown that small lipid-poor HDL has the strongest association with ABCA1-mediated cholesterol efflux, even in the presence of other HDL subpopulations.<sup>40</sup> Regarding the HDL cholesterol distribution, *CETP.E3L* mice mostly express small HDL, probably as a consequence of HDL remodeling by CETP. Apparently, the difference in levels of small HDL particles between plasma from *CETP.E3L* and *E3L* mice is not sufficient to affect ABCA1-mediated cholesterol efflux. The observation that CETP expression does not compromise ABCA1-mediated cholesterol efflux to HDL is in agreement with data from a previous study in rabbits treated with a CETP-inhibitor.<sup>41</sup>

Whereas CETP expression did not affect ABCA1-mediated efflux, it decreased the SR-BI-mediated cholesterol efflux. As different HDL subpopulations contribute equally to SR-BI-mediated cholesterol efflux,<sup>40</sup> and total HDL levels were lower in the plasma of *CETP.E3L* mice (especially HDL-1), this can thus easily explain the reduced SR-BI efflux. Nevertheless, ABCA1 and SR-BI do not constitute all the pathways that mediate cholesterol efflux from macrophages.<sup>42</sup> ABCG1 also mediates cholesterol efflux, and has been shown to be highly functional in inducing cholesterol efflux to HDL from CETP-deficient subjects.<sup>43</sup> Because ABCG1 and SR-BI both use HDL as cholesterol acceptor,<sup>40,43</sup> an additional effect of the CETP-induced lipoprotein shift on ABCG1-mediated efflux cannot be ruled out. Finally, it may be postulated that VLDL contributes to cholesterol efflux, similarly as has been documented for LDL.<sup>44</sup> However, even if VLDL contributes to cholesterol efflux, plasma from *CETP.E3L* mice showed a decreased SR-BI-mediated cholesterol efflux despite higher VLDL levels.

It remains to be elucidated whether CETP-induced reduced HDL will be rate-limiting for integrated RCT in vivo, ie, the transport of cholesterol from macrophages to the liver, leading to fecal secretion. A recent study has demonstrated that CETP inhibition in rabbits does not affect the clearance of HDL cholesterol,<sup>45</sup> and we have obtained initial data that CETP expression does not affect HDL-CE turnover in *E3L* mice (unpublished). However, our observations that CETP expression in *E3L* mice reduced cholesterol efflux in vitro, and strongly increased atherosclerosis in vivo, suggest that CETP reduced RCT in *E3L* mice.

Collectively, we have now shown that CETP is a clear pro-atherogenic factor in *E3L* mice. Because CETP also appeared pro-atherogenic in *apoe*<sup>-/-</sup> and *ldlr*<sup>-/-</sup> mice,<sup>14</sup> CETP thus seems to be consistently pro-atherogenic in the context of reduced hepatic uptake of apoB-containing lipoproteins, at least partly by further increasing the levels of

cholesterol-rich VLDL. In contrast, CETP is anti-atherogenic in *APOC3* and *LCAT* transgenic mice.<sup>12,13</sup> *APOC3* mice accumulate particularly TG-rich VLDL as a result of LPL inhibition, enabling a massive flux of TG from apoB-containing lipoproteins to HDL,<sup>46</sup> which may result in an accelerated clearance of TG-rich HDL particles via HL. As a consequence, smaller, cholesterol-poor HDL particles are formed,<sup>46</sup> which may have higher anti-atherogenic potential by more efficiently inducing cholesterol efflux. *LCAT* transgenic mice accumulate apoE-rich HDL-1, that is not efficiently cleared by the liver and therefore are more susceptible to atherosclerosis.<sup>12</sup> CETP expression in *LCAT* mice provides an extra pathway of delivering HDL cholesterol to the liver, resulting in normalization of the HDL particle size<sup>12</sup> and presumably increasing its cholesterol-accepting potency.

The *E3L* mouse model has been proven very suitable for testing hypolipidemic drugs that affect VLDL/LDL metabolism.<sup>19,47</sup> Atorvastatin,<sup>47</sup> rosuvastatin,<sup>48</sup> and gemfibrozil<sup>49</sup> reduced the levels of the VLDL/LDL in *E3L* mice comparable to humans. As the introduction of CETP results in the potential to modulate HDL cholesterol levels in addition to VLDL cholesterol levels, we anticipate that the *CETP.E3L* mouse will be suitable for the preclinical evaluation of HDL-increasing therapies (including CETP inhibitors), which constitute a novel target in the treatment of cardiovascular disease.

## Acknowledgments

We thank L.C. van der Zee-van Vark for excellent technical assistance.

## Sources of Funding

This work was performed in the framework of the Leiden Center for Cardiovascular Research LUMC-TNO, and supported by the Leiden University Medical Center (Gisela Thier Fellowship to P.C.N.R.), the Netherlands Organization for Scientific Research (NWO grant 908-02-097 and NWO VIDI grant 917.36.351 to P.C.N.R.; NWO grant 903-39-291 to L.M.H.), the Netherlands Heart Foundation (NHS grant 2003B136 to P.C.N.R.), and the Center for Medical Systems Biology (project 115 to L.M.H.). J.W.J. is an established clinical investigator of the Netherlands Heart Foundation (2001D032).

## Disclosures

None.

## References


- Hansson GK. Mechanisms of disease—inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352:1685–1695.
- Glass CK, Witztum JL. Atherosclerosis: the road ahead. *Cell*. 2001;104:503–516.
- Ha YC, Calvert GD, McIntosh GH, Barter PJ. A physiologic role for the esterified cholesterol transfer protein—in vivo studies in rabbits and pigs. *Metabolism-Clin Exp*. 1981;30:380–383.
- Gauthier A, Lau P, Zha XH, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. *Arterioscler Thromb Vasc Biol*. 2005;25:2177–2184.
- Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJG, Jukema JW, Luben R et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women—The prospective EPIC (European Prospective Investigation into Cancer and Nutrition)—Norfolk population study. *Circulation*. 2004;110:1418–1423.

6. Klerkx AHM, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJP. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). *Eur J Clin Invest.* 2004;34:21–28.
7. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Brusckhe AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. *N Engl J Med.* 1998;338:86–93.
8. Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M, Sagehashi Y, Kujiraoka T, Tanaka K, Hattori H, Sakai N, Nakajima N, Egashira T, Matsuzawa Y. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. *J Atheroscler Thromb.* 2004;11:110–121.
9. Zhong SB, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. *J Clin Invest.* 1996;97:2917–2923.
10. Jiao S, Cole TG, Kitchens RT, Pflieger B, Schonfeld G. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. *Metabolism.* 1990;39:155–160.
11. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary-cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice—dependence on natural flanking sequences. *J Clin Invest.* 1992;90:1290–1295.
12. Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt RF, Brewer HB Jr, Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. *J Biol Chem.* 1999;274:36912–36920.
13. Hayek T, Masuccimagoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. *J Clin Invest.* 1995;96:2071–2074.
14. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. *Arterioscler Thromb Vasc Biol.* 1999;19:1105–1110.
15. Grass DS, Saini U, Felkner RH, Wallace RE, Lago WJP, Young SG, Swanson ME. Transgenic mice expressing both human apolipoprotein-B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. *J Lipid Res.* 1995;36:1082–1091.
16. Zuckerman SH, Evans GF, Schelm JA, Eacho PI, Sandusky G. Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human ApoB100xCETP transgenic mice. *Arterioscler Thromb Vasc Biol.* 1999;19:1476–1483.
17. Getz GS, Reardon CA. Diet and murine atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2006;26:242–249.
18. Vandenmaagdenberg AMJM, Hofker MH, Krimpenfort PJA, Debruijn I, Vanvljmen B, Vanderboom H, Havekes LM, Frants RR. Transgenic mice carrying the apolipoprotein-E3-Leiden gene exhibit hyperlipoproteinemia. *J Biol Chem.* 1993;268:10540–10545.
19. Vanvljmen BJM, Vandenmaagdenberg AMJM, Gijbels MJJ, Vanderboom H, Hogenesch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3 Leiden transgenic mice. *J Clin Invest.* 1994;93:1403–1410.
20. Vanvljmen BJM, vanDijk KW, vantHof HB, vanGorp PJJ, vanderZee A, Vanderboom H, Breuer ML, Hofker MH, Havekes LM. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E\*2(Arg-158->Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E\*3-Leiden transgenic mice. *J Biol Chem.* 1996;271:30595–30602.
21. Berbee JFP, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PCN. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. *J Lipid Res.* 2005;46:297–306.
22. Speijer H, Groener JEM, Vanramshorst E, Vantol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. *Atherosclerosis.* 1991;90:159–168.
23. Burstein M, Morfin R. [Precipitation of alpha lipoproteins in serum by sodium phosphotungstate in the presence of magnesium chloride]. *Life Sci.* 1969;8:345–348.
24. Niemeijer-Kanters SDJM, Dallinga-Thie GM, Ruijter-Heijstek FC, Algra A, Erkelens DW, Banga JD, Jansen H. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. *Atherosclerosis.* 2001;156:209–216.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J Biol Chem.* 1951;193:265–275.
26. Fournier N, Atger V, Paul JL, Sturm M, Duverger N, Rothblat GH, Moatti N. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum. *Arterioscler Thromb Vasc Biol.* 2000;20:1283–1292.
27. Ji Y, Jian B, Wang N, Sun Y, Moya MDLL, Phillips MC, Rothblat GH, Swaney JB, Tall AR. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. *J Biol Chem.* 1997;272:20982–20985.
28. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis—a report from the committee on vascular-lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation.* 1995;92:1355–1374.
29. Gijbels MJJ, van der Cammen M, van der Laan LJW, Emeis JJ, Havekes LM, Hofker MH, Kraal G. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. *Atherosclerosis.* 1999;143:15–25.
30. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW, Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. *Arterioscler Thromb.* 1991;11:797–804.
31. Groot PHE, Vanvljmen BJM, Benson GM, Hofker MH, Schiffelers R, Vidgeonhart M, Havekes LM. Quantitative assessment of aortic atherosclerosis in APOE\*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. *Arterioscler Thromb Vasc Biol.* 1996;16:926–933.
32. vanVlijmen BJ, vanDijk KW, vantHof BH, vanGorp PJ, vanderZee A, Vanderboom H, Breuer ML, Hofker MH, Havekes LM. APOE\*2(158) transgenic mice develop a more severe hyperlipoproteinemic phenotype than APOE\*3-Leiden transgenic mice. *Circulation.* 1996;94:3032.
33. Tall AR. Plasma cholesteryl ester transfer protein. *J Lipid Res.* 1993;34:1255–1274.
34. ApplebaumBowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, Meyn S, Parrott C, Maeda N, Shamburek R, Brewer HB, SantamarinaFojo S. Hepatic lipase gene therapy in hepatic lipase-deficient mice—adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. *J Clin Invest.* 1996;97:799–805.
35. Masuccimagoulas L, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice—a novel mechanism signals changes in plasma cholesterol levels. *J Clin Invest.* 1996;97:154–161.
36. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. *J Clin Invest.* 2000;105:513–520.
37. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. *Nature.* 1996;383:728–731.
38. Kleemann R, Princen HMG, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJG, Kooistra T, Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE\*3-Leiden transgenic mice - Evidence for antiinflammatory effects of rosuvastatin. *Circulation.* 2003;108:1368–1374.
39. Zhang ZY, Yamashita S, Hirano K, Nakagawa-Toyama Y, Matsuyama A, Nishida M, Sakai N, Fukusawa M, Arai H, Mijagawa J, Matsuzawa Y. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. *Atherosclerosis.* 2001;159:67–75.
40. Asztalos BF, Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. *J Lipid Res.* 2005;46:2246–2253.
41. Kobayashi J, Okamoto H, Otake M, Bujo H, Saito Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. *Atherosclerosis.* 2002;162:131–135.

42. Duong M, Collins HL, Jin WJ, Zanotti I, Favari E, Rothblat GH. Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. *Arterioscler Thromb Vasc Biol.* 2006;26:541–547.
43. Matsuura F, Wang N, Chen WG, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. *J Clin Invest.* 2006;116:1435–1442.
44. Wang N, Lan DB, Chen WG, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. *Proc Natl Acad Sci U S A.* 2004;101:9774–9779.
45. Kee P, Caiazza D, Rye KA, Barrett PHR, Morehouse LA, Barter PJ. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma - In vivo studies in rabbits. *Arterioscler Thromb Vasc Biol.* 2006;26:884–890.
46. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajekshaul T, Agellon LB, Tall AR, Breslow JL. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high-density-lipoprotein levels, particle sizes, and metabolism—studies in transgenic mice. *J Clin Invest.* 1993;92:1143–1152.
47. Delsing DJ, Jukema JW, van de Wiel MA, Emeis JJ, van der LA, Havekes LM, Princen HM. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE\*3-Leiden transgenic mice. *J Cardiovasc Pharmacol.* 2003;42:63–70.
48. Delsing DJM, Post SM, Groenendijk M, Solaas K, Van der Boom H, van Duyvenvoorde W, De Wit ECM, Bloks VW, Kuipers F, Havekes LM, Princen HM. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE\*3-Leiden mice. *J Cardiovasc Pharmacol.* 2005;45:53–60.
49. van Vlijmen BJM, Pearce NJ, Bergo M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PHE. Apolipoprotein E\*3 Leiden transgenic mice as a test model for hypolipidaemic drugs. *Arzneimittel-Forschung-Drug Res.* 1998;48:396–402.



Online figure I. **Effect of CETP on cholesterol levels in E3L mice fed a Western-type diet containing 0.25% cholesterol.** E3L and CETP·E3L mice were fed a Western-type diet containing 0.25% cholesterol from 8 weeks of age (t=0). Fasted plasma was collected from E3L (white symbols) and CETP·E3L mice (black symbols) (n=11) at the indicated time points, and assayed for cholesterol (TC). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .



**Online Fig I**

# Arteriosclerosis, Thrombosis, and Vascular Biology



JOURNAL OF THE AMERICAN HEART ASSOCIATION

## **Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in *APOE\*3-Leiden* Mice**

Marit Westerterp, Caroline C. van der Hoogt, Willeke de Haan, Erik H. Offerman, Geesje M. Dallinga-Thie, J. Wouter Jukema, Louis M. Havekes and Patrick C.N. Rensen

*Arterioscler Thromb Vasc Biol.* 2006;26:2552-2559; originally published online August 31, 2006;

doi: 10.1161/01.ATV.0000243925.65265.3c

*Arteriosclerosis, Thrombosis, and Vascular Biology* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2006 American Heart Association, Inc. All rights reserved.

Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://atvb.ahajournals.org/content/26/11/2552>

Data Supplement (unedited) at:

<http://atvb.ahajournals.org/content/suppl/2006/09/05/01.ATV.0000243925.65265.3c.DC1.html>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:

<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:

<http://atvb.ahajournals.org/subscriptions/>